연구 보고서
121권_바이오의약품_항바이러스치료제를중심으로.pdf
개요
1. 항바이러스 치료제 연구개요
소득수준 향상, 인구의 고령화, 만성질환 관련 의약품에 대한 수요증가, 수명증가 등으로 인하여 전 세계적으로 의약품 시장이 성장하고 있는 가운데, 바이오 의약품의 연구 개발이 국내외 제약 산업에서 증대되고 있음 그 가운데 전 인류의 숙제인 에이즈 치료제 개발 및 간질환 인플루엔자 질환 치료제 개발의 기초가 되는 항바이러스 치료제 관련 연구 및 이를 활용한 치료제 개발, 의료기술 및 삶의 질 향상 기술개발에 대한 요구가 증대되고 있음
1) 항바이러스 치료제 연구의 정의 및 특징
바이러스란 세균보다 작아서 세균여과기(0.22um)로도 걸러질 수 없는 작은 입자(평균 0.1um 이하)로, 생존에 필요한 물질로 핵산(DNA 또는 RNA)과 소수의 단백질만을 가지고 있어 숙주에 의존하여 살아가는 생명체임
○ 바이러스로 인해 야기되는 질병에 대한 치료제로, 체내에 침입한 바이러스의 작용을 약하게 하거나 소멸하게 하는 약을 항바이러스 치료제라 함......계속
★ 첨부파일 다운로드가 안되시는 이용자께서는 아래 링크를 클릭하세요~!
바이오의약품 기술개발 동향(유전자치료제를 중심으로) 보러가기~!!
목차
1. 항바이러스 치료제 연구개요
1) 항바이러스 치료제연구의 정의 및 특징 ················································· 1
2) 항바이러스 치료제 연구 ············································································ 2
3) 항바이러스 치료제연구의 연구영역 및 기술분류 ·································· 3
2. 서지분석
가. 특허분석 ········································································································· 4
1) 해외특허로 살펴본 항바이러스 치료제 분야 세계동향 ························ 5
2) 해외에 출원된 특허로 살펴본 항바이러스 치료제분야 국내동향 ····· 11
3) 한국 특허청에 출원된 살펴본 항바이러스 치료제분야 국내동향 ····· 14
나. 논문분석 ······································································································ 19
1) 논문으로 살펴본 항바이러스 치료제분야 세계동향 ···························· 19
2) 논문으로 살펴본 항바이러스 치료제분야 국내동향 ···························· 26
3. 산업동향 및 기술개발 동향
가. 항바이러스 치료제 관련시장 ···································································· 32
1) 세계시장 현황 및 전망 ··········································································· 32
2) 산업동향 ···································································································· 33
3) 항바이러스 치료제 분야 국내시장 ························································ 36
나. 기술개발동향 ······························································································· 38
1) 세계동향 ···································································································· 38
2) 국내동향 ···································································································· 40
4. 시사점 및 대응방향
5. 참고문헌
지식